Moreover, we question whether the frequently studied TCR targets NY-ESO-1 and MAGE-A4 are optimal targets for the majority of ovarian cancer patients, since the mean expression levels were low in the included TCGA OVCA samples (mean read count 3⁄4 100). This evidence concerns the gene MAGEA4 and ovarian carcinoma.